IOPtima Overview
IOPtima is a rapidly growing company focused on developing minimally invasive and innovative surgical ophthalmic devices. Its flagship product, the IOPtimate, is a surgical system for the treatment of glaucoma that utilizes CO2 laser technology to significantly reduce internal eye pressure without penetrating the eye. The company also offers a line of patented eye drops to treat ocular surface diseases. IOPtima is a Kanghong Pharmaceutical company.
Cumulative Funding Raised Over Time ($)
$7.2MNov 2015
Latest News
growth-positive
Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company
Chengdu Kanghong Pharma Group has acquired a 41% stake in Tel Aviv-based medical technology company IOPtima for $17.2 million, solidifying its ownership. This investment brings Chengdu Kanghong Pharmas stake in IOPtima to 60%, as they had previously acquired a 19% stake in 2017. Chengdu Kanghong Pharma plans to acquire the remaining stake in two additional stages. IOPtima develops minimally invasive devices for eye surgeries, with its flagship product, IOPtimate, being a laser-based surgical system for the treatment of Glaucoma. The company has regulatory approval for marketing the system in several territories.
InvestmentAcquisition
growth-positive
Chengdu Kanghong Pharma buys Israel's IOPtima for $56m
BioLight Israeli Life Sciences Investments Ltd. has completed the sale of its subsidiary, IOPtima, to Chengdu Kanghong Pharmaceutical Group. The acquisition will generate $23-27.3 million in cash flow for BioLight. Chengdu Kanghong will also become a distributor of IOPtimas products in China. BioLights share price increased by over 10% as a result of the deal.
AcquisitionInvestment
growth-positive
IOPtima launches Lipitear phospholipid microemulsion
IOPtima has launched Lipitear, a phospholipid-based microemulsion that helps restore the ocular surface and enhances corneal re-epithelization after surgery. It reduces symptoms of ocular surface disorder and prevents tear evaporation. The device is currently marketed in Europe under a CE mark but is not yet registered in the United States.
Customers
growth-positive
IOPtima launches iLid CO2 laser kit for blepharoplasty
IOPtima has launched the iLid CO2 laser kit, designed for oculoplastic surgeons to perform CO2 laser-assisted blepharoplasty. The kit offers several benefits, including reduced bruising, swelling, and pain, shorter recovery period, and better cosmetic results. It is based on the IOPtiMate system used for CO2 laser-assisted sclerotomy surgery for glaucoma.
Customers
growth-positive
BioLight to sell IOPtima to Chinese co
BioLight Israeli Life Sciences Investments Ltd. has signed a memorandum of understanding for the sale of its leading product, the only one directly generating revenue for the company, to a Chinese company, Chengdu Kanghong Pharma. Chengdu Kanghong Pharma will invest $7 million in IOPtima for 19% of that companys shares at a $30 million company value. The Chinese company will receive an exclusive license to market IOPtimas product in China. After six months, the Chinese company will acquire additional shares in IOPtima from the existing shareholders, including BioLight, thereby increasing Chengdu Kanghong Pharmas IOPtima stake to 60%, for $17.2 million, reflected a $42 million company value.
AcquisitionInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.2M |
| Last funding | $7.2M |
| Stage | Acquired |
| Rounds | 1 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.ioptima.com |
Locations
Leshem St 10, Caesarea, Israel
Photos & Videos
2 item(s)
IOPtima Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
SensingLaserTags (13)
medical-deviceseye-diseasesminimally-invasivesurgerylasersglaucomaophthalmologyhospitalspharma-companiesclinicshealthcare-providersmedical-technologiesoptronicsGeographic Markets
GlobalIOPtima Financials
$7.2M
Total funding
Undisclosed
Capital raised
$7.2M
Last funding
Acquired
Funding stage
1
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$7.2MNov 2015
Private Equity Funding
B Round
Nov 2015
$7.2M
Infinity China, Diamond Bio Fund , BIOLIGHT Life Sciences
Public Offering / Exit
MNAEvent
Sep 2018
$56M
IOPtima Lifecycle
Cumulative Funding Raised Over Time
$7.2MNov 2015
All Events
B Round
Nov 2015
$7.2M
Infinity China, Diamond Bio Fund , BIOLIGHT Life Sciences
MNAEvent
Sep 2018
$56M
IOPtima News
9 articles
growth-positive
Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company
Chengdu Kanghong Pharma Group has acquired a 41% stake in Tel Aviv-based medical technology company IOPtima for $17.2 million, solidifying its ownership. This investment brings Chengdu Kanghong Pharmas stake in IOPtima to 60%, as they had previously acquired a 19% stake in 2017. Chengdu Kanghong Pharma plans to acquire the remaining stake in two additional stages. IOPtima develops minimally invasive devices for eye surgeries, with its flagship product, IOPtimate, being a laser-based surgical system for the treatment of Glaucoma. The company has regulatory approval for marketing the system in several territories.
InvestmentAcquisition
growth-positive
Chengdu Kanghong Pharma buys Israel's IOPtima for $56m
BioLight Israeli Life Sciences Investments Ltd. has completed the sale of its subsidiary, IOPtima, to Chengdu Kanghong Pharmaceutical Group. The acquisition will generate $23-27.3 million in cash flow for BioLight. Chengdu Kanghong will also become a distributor of IOPtimas products in China. BioLights share price increased by over 10% as a result of the deal.
AcquisitionInvestment
growth-positive
IOPtima launches Lipitear phospholipid microemulsion
IOPtima has launched Lipitear, a phospholipid-based microemulsion that helps restore the ocular surface and enhances corneal re-epithelization after surgery. It reduces symptoms of ocular surface disorder and prevents tear evaporation. The device is currently marketed in Europe under a CE mark but is not yet registered in the United States.
Customers
growth-positive
IOPtima launches iLid CO2 laser kit for blepharoplasty
IOPtima has launched the iLid CO2 laser kit, designed for oculoplastic surgeons to perform CO2 laser-assisted blepharoplasty. The kit offers several benefits, including reduced bruising, swelling, and pain, shorter recovery period, and better cosmetic results. It is based on the IOPtiMate system used for CO2 laser-assisted sclerotomy surgery for glaucoma.
Customers
growth-positive
BioLight to sell IOPtima to Chinese co
BioLight Israeli Life Sciences Investments Ltd. has signed a memorandum of understanding for the sale of its leading product, the only one directly generating revenue for the company, to a Chinese company, Chengdu Kanghong Pharma. Chengdu Kanghong Pharma will invest $7 million in IOPtima for 19% of that companys shares at a $30 million company value. The Chinese company will receive an exclusive license to market IOPtimas product in China. After six months, the Chinese company will acquire additional shares in IOPtima from the existing shareholders, including BioLight, thereby increasing Chengdu Kanghong Pharmas IOPtima stake to 60%, for $17.2 million, reflected a $42 million company value.
AcquisitionInvestment
growth-positive
Bio Light's IOPtiMate[TM] System Receives Regulatory Approval in Canada
Bio Light Israeli Life Sciences Investments Ltd. has received approval from the Canadian Medical Devices Bureau for its IOPtiMate system for the treatment of glaucoma. This approval allows the company to commercialize the surgical system in Canada. The IOPtiMate system enables a non-penetrating, CO2 laser-assisted procedure known as CLASS to reduce elevated intraocular pressure. The company is primarily marketing the system to leading physicians and medical centers in Asia and Europe. The company has also signed a joint-financing agreement with two Asia-based venture capital firms to support the global commercialization of the IOPtiMate system.
CustomersPartnersInvestment
growth-positive
BioLight Eyes Chinese Glaucoma Market, Raises US$5.5 Million - Asian Scientist Magazine
BioLight, an Israeli investment group, has raised $5.5 million in equity financing. The company plans to enter the Chinese glaucoma market, which is the largest in the world. BioLights subsidiary, IOPtima Ltd., has received approval from the China Food and Drug Administration to market and sell the IOPtiMate™ system, a surgical device for glaucoma treatment. The financing and approval will support the expansion of marketing and sales activities for the IOPtiMate™ system, as well as the advancement of other products into clinical trials.
Investment
N/A
https://www.bioopticsworld.com/articles/2009/11/ioptima-receives-europea-patent-approval-for-laser-system-for-treatment-of-glaucoma.html
The article discusses the use of a security service by www.bioopticsworld.com to protect against online attacks.
growth-positive
Israel's IOPtima shines a light at the end of the glaucoma tunnel
Israeli startup IOPtima has developed a breakthrough treatment for glaucoma using a carbon dioxide laser technology. The companys OT134 device allows eye surgeons to easily operate on glaucoma patients, making the procedure simpler and safer. The treatment has been successful in pre-clinical trials and has garnered interest from eye surgeons worldwide. IOPtimas technology offers better efficacy and safety advantages compared to traditional drug and surgery therapies for glaucoma. The treatment has the potential to significantly improve glaucoma surgery outcomes and reduce complications. It also has the potential to open up possibilities for glaucoma surgery in developing countries where prolonged treatments with eye drops are not feasible. The company aims to make glaucoma surgery fast, convenient, effective, and safe.
Customers
IOPtima Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
IOPtima Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 513264424 |
| Crunchbase | ioptima |
| Phone | +972723922081 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-10-01T00:00:00.000Z |
| Created | 2014-07-21T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by Chengdu Kanghong Pharmaceutical Group on Sep, 2018 |